Table 2.
Selected series outcomes of relapsed or refractory PCNSL patients treated with SRS
| Author | n | Single or Multi-institutional | Data Collection | Median Margin Dose | Median Tumor Volume | 1 Year PFS/OS | 1 year LC |
| Sakamoto et al. 10 | 9 | Single | Retrospective | 12 Gy | 3.5 cm3 | 22%/58% | 89% |
| Kenai et al. 17 | 22 | Single | Retrospective | 16.5 Gy | 4 cm3 | Not Reported | 100% |
| Matsumoto et al. 18 | 6 | Single | Retrospective | Not Reported | Not Reported | Median PFS/OS: 11 months/17 months | 67% |
| Kumar et al. 19 | 14 | Single | Retrospective | 15.5 Gy | 6.7 cm3 | Median PFS/OS: 4 months/9.5 months | 78% |
| Current Study | 23 | Multi | Retrospective | 15 Gy | 4 cm3 | 55%/47% | 75% |
PCNSL Primary Central Nervous System Lymphoma, SRS Stereotactic radiosurgery, PFS Progression-free survival, OS Overall survival, LC Local Control